1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Respiratory Tract Inflammatory Disorders - Pipeline Review, H1 2014

Respiratory Tract Inflammatory Disorders - Pipeline Review, H1 2014

  • March 2014
  • -
  • Global Markets Direct
  • -
  • 42 pages

Respiratory Tract Inflammatory Disorders - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Respiratory Tract Inflammatory Disorders - Pipeline Review, H1 2014’, provides an overview of the Respiratory Tract Inflammatory Disorders’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Respiratory Tract Inflammatory Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Tract Inflammatory Disorders and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Respiratory Tract Inflammatory Disorders
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Respiratory Tract Inflammatory Disorders and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Respiratory Tract Inflammatory Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Respiratory Tract Inflammatory Disorders pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Respiratory Tract Inflammatory Disorders
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Respiratory Tract Inflammatory Disorders pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Respiratory Tract Inflammatory Disorders - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Respiratory Tract Inflammatory Disorders Overview 6
Therapeutics Development 7
Pipeline Products for Respiratory Tract Inflammatory Disorders - Overview 7
Pipeline Products for Respiratory Tract Inflammatory Disorders - Comparative Analysis 8
Respiratory Tract Inflammatory Disorders - Therapeutics under Development by Companies 9
Respiratory Tract Inflammatory Disorders - Therapeutics under Investigation by Universities/Institutes 10
Respiratory Tract Inflammatory Disorders - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Respiratory Tract Inflammatory Disorders - Products under Development by Companies 13
Respiratory Tract Inflammatory Disorders - Products under Investigation by Universities/Institutes 14
Respiratory Tract Inflammatory Disorders - Companies Involved in Therapeutics Development 15
Merck and Co., Inc. 15
UCB S.A. 16
Verona Pharma Plc 17
GlycoMar Limited 18
Trino Therapeutics Ltd 19
Covigilance sro 20
Respiratory Tract Inflammatory Disorders - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
COVXPB-21 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
GLY-145 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
PH-5 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Small Molecules to Inhibit Cells Expressing CD44 for Respiratory Tract Inflammatory Disorders - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
SPA-0355 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Inhaled Dissociated Steroid For Respiratory Disorders - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
NAIPs - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
GLY-079 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
VR-942 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
Respiratory Tract Inflammatory Disorders - Dormant Projects 39
Respiratory Tract Inflammatory Disorders - Product Development Milestones 40
Featured News and Press Releases 40
Jan 02, 2012: Orchid Pharma Reports Successful Completion Of Phase I Study Of OCID 2987 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42

List of Tables

Number of Products under Development for Respiratory Tract Inflammatory Disorders, H1 2014 7
Number of Products under Development for Respiratory Tract Inflammatory Disorders - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Products under Investigation by Universities/Institutes, H1 2014 14
Respiratory Tract Inflammatory Disorders - Pipeline by Merck and Co., Inc., H1 2014 15
Respiratory Tract Inflammatory Disorders - Pipeline by UCB S.A., H1 2014 16
Respiratory Tract Inflammatory Disorders - Pipeline by Verona Pharma Plc, H1 2014 17
Respiratory Tract Inflammatory Disorders - Pipeline by GlycoMar Limited, H1 2014 18
Respiratory Tract Inflammatory Disorders - Pipeline by Trino Therapeutics Ltd, H1 2014 19
Respiratory Tract Inflammatory Disorders - Pipeline by Covigilance sro, H1 2014 20
Assessment by Monotherapy Products, H1 2014 21
Number of Products by Stage and Target, H1 2014 23
Number of Products by Stage and Mechanism of Action, H1 2014 25
Number of Products by Stage and Route of Administration, H1 2014 27
Number of Products by Stage and Molecule Type, H1 2014 29
Respiratory Tract Inflammatory Disorders - Dormant Projects, H1 2014 39

List of Figures

Number of Products under Development for Respiratory Tract Inflammatory Disorders, H1 2014 7
Number of Products under Development for Respiratory Tract Inflammatory Disorders - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 12
Assessment by Monotherapy Products, H1 2014 21
Number of Products by Top 10 Target, H1 2014 22
Number of Products by Stage and Top 10 Target, H1 2014 23
Number of Products by Top 10 Mechanism of Action, H1 2014 24
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 25
Number of Products by Top 10 Route of Administration, H1 2014 26
Number of Products by Stage and Top 10 Route of Administration, H1 2014 27
Number of Products by Top 10 Molecule Type, H1 2014 28
Number of Products by Stage and Top 10 Molecule Type, H1 2014 29

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in Denmark - Forecast

  • December 2016
    12 pages
  • Therapy  

  • Denmark  

View report >

Related Market Segments :

Therapy
Respiratory Disease

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.